Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021
Biocon Biologics and Viatris co-developed the products
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
Second interchangeable biosimilar product approved by agency
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Subscribe To Our Newsletter & Stay Updated
